ESCRS 2023: Thomas Bosshard discusses Oertli's 3-platform approach

News
Video

At this year's ESCRS meeting, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach.

At this year's European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Vienna, Austria, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach. Here's our conversation, live from the congress floor.

Editor's note: This transcript has been edited for clarity.

Thomas Bosshard: Hey guys my name is Thomas, Thomas Bosshard. I'm the co-owner and CO-CEO of Oertli Instruments in Switzerland. We are proud to bring to the ESCRS, of course, our 3-platform strategy with the OS4, the CataRhex 3 and the Faros, which are highly renowned for super dynamic cataract surgery and vitrectomy surgery. With all its features, peripheral products and of course, along with it, our highly dynamic team, which is here for our customers and partners.

Probably the most interesting thing which we are currently featuring and getting more and more wild and exciting about is our Speed Mode with our with our CataRhex 3 and all our other platforms, which is a highly effective tool for safer and simpler surgery, whether it's in cataract or vitrectomy procedures.

In 2024, you should be excited about quite great pipeline which we are about to start early over the next few years which is to come. It's going to be a very interesting time from 2024 on, at and around Oertli Instruments.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.